234 related articles for article (PubMed ID: 24396495)
21. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
22. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
[TBL] [Abstract][Full Text] [Related]
23. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
24. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
26. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
[TBL] [Abstract][Full Text] [Related]
27. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
28. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
Innao P; Pothisuwan M; Pengsa P
Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
[TBL] [Abstract][Full Text] [Related]
29. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
[TBL] [Abstract][Full Text] [Related]
30. The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study.
Varughese E; Kondalsamy-Chennakesavan S; Obermair A
J Ovarian Res; 2012 Mar; 5():11. PubMed ID: 22436532
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
[TBL] [Abstract][Full Text] [Related]
32. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Rustin GJ; van der Burg ME; Griffin CL; Guthrie D; Lamont A; Jayson GC; Kristensen G; Mediola C; Coens C; Qian W; Parmar MK; Swart AM; ;
Lancet; 2010 Oct; 376(9747):1155-63. PubMed ID: 20888993
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
Alexander VM; Gordon AN; Howard DH; Khanna N
Int J Gynecol Cancer; 2017 Sep; 27(7):1333-1342. PubMed ID: 28692633
[TBL] [Abstract][Full Text] [Related]
34. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
Pignata S; Cannella L; Leopardo D; Bruni GS; Facchini G; Pisano C
Ann Oncol; 2011 Dec; 22 Suppl 8():viii40-viii44. PubMed ID: 22180398
[TBL] [Abstract][Full Text] [Related]
35. Update on the treatment of recurrent ovarian cancer.
Eltabbakh GH; Goodrich S
Womens Health (Lond); 2006 Jan; 2(1):127-39. PubMed ID: 19803933
[TBL] [Abstract][Full Text] [Related]
36. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
37. How to follow-up patients with epithelial ovarian cancer.
Miller RE; Rustin GJ
Curr Opin Oncol; 2010 Sep; 22(5):498-502. PubMed ID: 20498597
[TBL] [Abstract][Full Text] [Related]
38. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
Cho H; Hur HW; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
Cancer Immunol Immunother; 2009 Jan; 58(1):15-23. PubMed ID: 18414853
[TBL] [Abstract][Full Text] [Related]
39. Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.
Dunton CJ; Hutchcraft ML; Bullock RG; Northrop LE; Ueland FR
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441373
[TBL] [Abstract][Full Text] [Related]
40. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.
Goto T; Takano M; Watanabe A; Miyamoto M; Kato M; Hirata J; Sasa H; Furuya K
Int J Gynecol Cancer; 2011 Feb; 21(2):263-8. PubMed ID: 21270609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
